Initial Therapeutics
Initial Therapeutics, Inc. is a preclinical-stage biotechnology company in South San Francisco, California, discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in its earliest stages. Its proprietary STOPS platform — Selective Termination of Protein Synthesis — intercepts the translation of a target protein inside the exit tunnel of the ribosome, recognizing the nascent primary linear sequence rather than a fully folded three-dimensional structure, an approach the company positions as starkly differentiated from targeted protein degradation and from interventions that can only act on proteins after they are fully formed. The company launched publicly on May 1, 2023 with a $75 million Series A from Apple Tree Partners, was co-founded with academic scientists Jamie H. D. Cate (UC Berkeley), Brian Paegel (UC Irvine) and Kevan Shokat (UCSF/UC Berkeley), and builds on ribosome biochemistry, proteomics, medicinal chemistry, DNA-encoded library technology and chemical genetics, with early programs aimed at oncology targets long considered undruggable. Initial Therapeutics is a therapeutics discovery company, not a software vendor: it publishes a small marketing website and no public API, SDK, developer portal or machine-readable contract of any kind.
Initial Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Drug Discovery, and Small Molecule.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Initial Therapeutics
11 quoted statements, read from Initial Therapeutics's own page on 2026-11-09.
TERMSPrivacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Initial Therapeutics
13 quoted statements, read from Initial Therapeutics's own page on 2026-11-09.
PRIVACYEligibility 1
Who may sign up and where, quoted from its own terms.
Initial Therapeutics
6 quoted statements, read from Initial Therapeutics's own page on 2026-11-09.
ELIGIBILITYAI Preferences 1
Its stance on AI training, inference and agents, quoted from its own pages.
Initial Therapeutics
1 quoted statement, read from Initial Therapeutics's own page on 2026-11-09.
AI PREFSData License 1
How its data and outputs may be reused, quoted from its own terms.
Initial Therapeutics
1 quoted statement, read from Initial Therapeutics's own page on 2026-11-09.
LICENSESecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Documentation 1
Reference material describing how the API behaves
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Commercial 4
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.